 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
New P1 trial: Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension (clinicaltrials.gov) - Oct 16, 2024
P1, N=40, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- || GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
Trial completion, Trial completion date, Trial primary completion date: GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers (clinicaltrials.gov) - Nov 15, 2023
P1, N=24, Completed, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Not yet recruiting --> Completed | Trial completion date: Feb 2024 --> Oct 2023 | Trial primary completion date: Dec 2023 --> Aug 2023
- ||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
Trial completion, Trial completion date, Trial primary completion date: A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers (clinicaltrials.gov) - Nov 14, 2023
P1, N=54, Completed, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Not yet recruiting --> Completed | Trial completion date: Feb 2024 --> Oct 2023 | Trial primary completion date: Dec 2023 --> Aug 2023 Recruiting --> Completed | Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jun 2023 --> Sep 2023
- || GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
New P1 trial: GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers (clinicaltrials.gov) - Apr 18, 2023
P1, N=24, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- ||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
New P1 trial: A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers (clinicaltrials.gov) - Mar 29, 2023
P1, N=54, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- |||||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
Enrollment open: To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection (clinicaltrials.gov) - Aug 4, 2022
P3, N=552, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Recruiting --> Completed | Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jun 2023 --> Sep 2023 Not yet recruiting --> Recruiting
- |||||||||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
New P3 trial: To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection (clinicaltrials.gov) - Jul 26, 2022
P3, N=552, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- |||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
Trial completion, Trial primary completion date: A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza (clinicaltrials.gov) - Jul 26, 2022
P2, N=216, Completed, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Aug 2021 --> Dec 2021
- || GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
Trial completion, Trial completion date, Trial primary completion date: A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers (clinicaltrials.gov) - Dec 10, 2021
P1, N=6, Completed, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Recruiting --> Completed | Trial primary completion date: Aug 2021 --> Dec 2021 Not yet recruiting --> Completed | Trial completion date: Mar 2022 --> Nov 2021 | Trial primary completion date: Mar 2022 --> Nov 2021
- || GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
New P1 trial: A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers (clinicaltrials.gov) - Nov 2, 2021
P1, N=6, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- ||||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
New P2 trial: A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza (clinicaltrials.gov) - Feb 3, 2021
P2, N=216, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- ||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
New P1 trial: Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects (clinicaltrials.gov) - Jan 27, 2021
P1, N=56, Completed, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.